Once-weekly cagrilintide Phase II weight-management trial
Mean weight reductions ranged 6.0%-10.8% across cagrilintide doses versus 3.0% placebo; 4.5 mg produced 10.8% versus 9.0% with liraglutide.
What this study tells us
Participants were assigned to comparison groups by chance, usually with placebo and/or blinding to reduce bias. This is a strong design for testing cause and effect, but the population, duration and endpoints still limit what can be concluded.
Adults with overweight/obesity without diabetes
n=706
Mean weight reductions ranged 6.0%-10.8% across cagrilintide doses versus 3.0% placebo; 4.5 mg produced 10.8% versus 9.0% with liraglutide.
Phase II; not the same evidence level as an approved weight-management medicine and not evidence for unregulated products.
Need help with terms such as randomized, placebo, endpoint or sample size? Open the glossary →
Key result
Mean weight reductions ranged 6.0%-10.8% across cagrilintide doses versus 3.0% placebo; 4.5 mg produced 10.8% versus 9.0% with liraglutide.